(HealthDay News) — For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of ...

small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity Terns plans to initiate a Phase 2 clinical trial in early second quarter of 2025 with initial 12-week data expected in the ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Who needs Ozempic to stop feeling hungry? Yes, the active ingredient semaglutide in the weight loss wonder drug helps to keep ...

These glucagon-like peptide-1 (GLP-1) medications are in high demand as options for weight loss, and many healthcare ...

Some of these peptide medications include glucagon-like peptide-1 (GLP-1) receptor agonists. They also include a combination of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor ...

Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...

GLP-1s seem to be everywhere. The appetite suppressant drugs, with brand names like Ozempic and Wegovy, have grown in ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...